Global Giant Cell Arteritis Therapeutic Supply, Demand and Key Producers, 2023-2029

Global Giant Cell Arteritis Therapeutic Supply, Demand and Key Producers, 2023-2029

The global Giant Cell Arteritis Therapeutic market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Giant cell arteritis (GCA) is a granulomatous medium and large-vessel vasculitis. It is the most common form of systemic vasculitis, with an incidence of between 15 and 25 cases per 100,000 persons over 50 years of age.

This report studies the global Giant Cell Arteritis Therapeutic demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Giant Cell Arteritis Therapeutic, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Giant Cell Arteritis Therapeutic that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Giant Cell Arteritis Therapeutic total market, 2018-2029, (USD Million)

Global Giant Cell Arteritis Therapeutic total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Giant Cell Arteritis Therapeutic total market, key domestic companies and share, (USD Million)

Global Giant Cell Arteritis Therapeutic revenue by player and market share 2018-2023, (USD Million)

Global Giant Cell Arteritis Therapeutic total market by Type, CAGR, 2018-2029, (USD Million)

Global Giant Cell Arteritis Therapeutic total market by Application, CAGR, 2018-2029, (USD Million)

This reports profiles major players in the global Giant Cell Arteritis Therapeutic market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, Kiniksa Pharmaceuticals, Ltd., Regeneron, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Novartis AG, AbbVie, Inc., Bristol-Myers Squibb Company and Abbott, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Giant Cell Arteritis Therapeutic market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Giant Cell Arteritis Therapeutic Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Giant Cell Arteritis Therapeutic Market, Segmentation by Type
Prednisone
Methotrexate
Tocilizumab
Aspirin

Global Giant Cell Arteritis Therapeutic Market, Segmentation by Application
Corticosteroids
Immunosuppressive Agents
Anticoagulants
Others

Companies Profiled:
Sanofi
Kiniksa Pharmaceuticals, Ltd.
Regeneron
GlaxoSmithKline plc
F. Hoffmann-La Roche Ltd.
Novartis AG
AbbVie, Inc.
Bristol-Myers Squibb Company
Abbott
Johnson & Johnson Services, Inc.
Johns Hopkins Hospital
Fortis Healthcare
American College of Rheumatology
Duke University Health System
Lahey Clinic Foundation

Key Questions Answered

1. How big is the global Giant Cell Arteritis Therapeutic market?

2. What is the demand of the global Giant Cell Arteritis Therapeutic market?

3. What is the year over year growth of the global Giant Cell Arteritis Therapeutic market?

4. What is the total value of the global Giant Cell Arteritis Therapeutic market?

5. Who are the major players in the global Giant Cell Arteritis Therapeutic market?

6. What are the growth factors driving the market demand?